Hoesseini A, van Leeuwen N, Offerman MPJ, et al. - Given that OncologIQ is a prognostic model that predicts the probability of overall survival (OS) in patients with head and neck squamous cell carcinoma (HNSCC), researchers sought to externally validate and update the model with new prognostic factors and translate it into a clinically useful tool. A total of 2,189 patients with primary HNSCC who were eligible for curative treatment were included in the study. Using the C‐statistic, discriminative performance was determined. This study allowed for the external validation and recalibration of the OncologIQ prognostic survival model for patients with primary HNC who were candidates for curative treatment. Because of systematic underestimation of OS in the new patient population, recalibration was required. Smoking, pack‐years, BMI, weight loss, WHO performance, and socioeconomic status were added as new prognostic variables, which improved OncologIQ's discriminative performance. The model was turned into a clinically useful tool that allows for up‐to‐date personalized patient counselling during treatment decision consultations.